Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series-Reference-Cited by-同舟云学术

Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series

Published:2022-03-02 Issue:4 Volume:27 Page:e350-e352
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Harris Jessica P¹^ORCID,Postow Michael A²³,Faleck David M¹³^ORCID

Affiliation:

1. Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Melanoma Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

3. Weill Cornell Medical College, New York, NY, USA

Abstract

Abstract Immune checkpoint inhibitor-related colitis is a common complication of immunotherapy use in patients with cancer. Current guidelines recommend treatment with standard dose infliximab (IFX) for corticosteroid-refractory colitis; however, this case series suggests IFX dose escalation may be a viable treatment option for refractory cases.

Funder

National Institutes of Health

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/27/4/e350/43287367/oyac019.pdf

Reference10 articles.

1. Enterocolitis due to immune checkpoint inhibitors: a systematic review.;Soularue;Gut.,2018

2. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis.;Wang;Oncoimmunology.,2017